Lisergamida
Les amides de l'àcid lisèrgic es coneixen col·lectivament com a lisergamides, i inclouen una sèrie de compostos amb una potent activitat agonista i/o antagonista en diversos receptors de la serotonina i la dopamina. Les lisergamides contenen una estructura incrustada de triptamina i, com a resultat, poden produir efectes similars, sovint psicodèlics, als de les autèntiques triptamines.[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]
Referències
[modifica]- ↑ «Psychotomimetic drugs; chemical and pharmacological aspects». Acta Physiologica et Pharmacologica Neerlandica, vol. 8, 6-1959, pàg. 240–58. PMID: 13852489.
- ↑ Pioch RP, "LYSERGIC ACID AMIDES", US patent 2997470, publicada 1956-03-05, emesa 1961-08-22
- ↑ «Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives». Journal of Medicinal Chemistry, vol. 28, 9, 9-1985, pàg. 1252–1255. DOI: 10.1021/jm00147a022. PMID: 4032428.
- ↑ «Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives». Pharmacology, Biochemistry, and Behavior, vol. 47, 3, 3-1994, pàg. 667–673. DOI: 10.1016/0091-3057(94)90172-4. PMID: 8208787.
- ↑ «LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors». Psychopharmacology, vol. 118, 4, 4-1995, pàg. 401–409. DOI: 10.1007/BF02245940. PMID: 7568626.
- ↑ «Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD)». Journal of Medicinal Chemistry, vol. 45, 19, 9-2002, pàg. 4344–4349. DOI: 10.1021/jm020153s. PMID: 12213075.
- ↑ «Ergot and its alkaloids». American Journal of Pharmaceutical Education, vol. 70, 5, 10-2006, pàg. 98. DOI: 10.5688/aj700598. PMC: 1637017. PMID: 17149427.
- ↑ «The pharmacology of lysergic acid diethylamide: a review». CNS Neuroscience & Therapeutics, vol. 14, 4, 2008, pàg. 295–314. DOI: 10.1111/j.1755-5949.2008.00059.x. PMC: 6494066. PMID: 19040555.
- ↑ «Chemistry and Structure-Activity Relationships of Psychedelics». Current Topics in Behavioral Neurosciences, vol. 36, 2017, pàg. 1–43. DOI: 10.1007/7854_2017_475. PMID: 28401524.
- ↑ «Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)». Drug Testing and Analysis, vol. 8, 9, 9-2016, pàg. 891–902. DOI: 10.1002/dta.1884. PMC: 4829483. PMID: 26456305.
- ↑ «Return of the lysergamides. Part II: Analytical and behavioural characterization of N6 -allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)». Drug Testing and Analysis, vol. 9, 1, 1-2017, pàg. 38–50. DOI: 10.1002/dta.1985. PMC: 5411264. PMID: 27265891.
- ↑ «Return of the lysergamides. Part III: Analytical characterization of N6 -ethyl-6-norlysergic acid diethylamide (ETH-LAD) and 1-propionyl ETH-LAD (1P-ETH-LAD)». Drug Testing and Analysis, vol. 9, 10, 10-2017, pàg. 1641–1649. DOI: 10.1002/dta.2196. PMC: 6230477. PMID: 28342178.
- ↑ «Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)». Drug Testing and Analysis, vol. 10, 2, 2-2018, pàg. 310–322. DOI: 10.1002/dta.2222. PMC: 6230476. PMID: 28585392.
- ↑ «Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)». Drug Testing and Analysis, vol. 11, 8, 8-2019, pàg. 1122–1133. DOI: 10.1002/dta.2613. PMC: 6899222. PMID: 31083768.
- ↑ «Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA)». Psychopharmacology, vol. 236, 2, 2-2019, pàg. 799–808. DOI: 10.1007/s00213-018-5055-9. PMC: 6848745. PMID: 30298278.